Article PDF
References
S. Lovestone, M. Thambisetty. Biomarkers for Alzheimer’s Disease Trials — Biomarkers for What ? A Discussion Paper. J Nutr Health Aging. 2009; 13(4):334–336
P.S. Aisen. Interpreting Biomarker Data in Therapeutic Trials. J Nutr Health Aging. 2009; 13(4):337–338
C. Sampaio. Biomarkers in Clinical Trials of Alzheimer Disease (AD): What Is Expected from Regulatory Agencies? J Nutr Health Aging. 2009; 13(4):339–340
E.R. Siemers. How Can We Recognize “Disease Modification” Effects? J Nutr Health Aging. 2009; 13(4):341–343
P.J. Visser. Use of Biomarkers To Select The Target Population For Clinical Trials in Subjects with Mild Cognitive Impairment, J Nutr Health Aging. 2009; 13(4):344–345
A. Nordberg. Molecular Imaging Markers in Clinical Trials in Alzheimer’s Disease. J Nutr Health Aging. 2009; 13(4):346–347
G.B. Frisoni Neuro-Imaging: Structural And Functional Imaging. J Nutr Health Aging. 2009; 13(4):348–349
N.C. Fox, J. Kennedy. Structural Imaging Markers for Therapeutic Trials in Alzheimer’s Disease. J Nutr Health Aging. 2009; 13(4):350–352
W.M. van Der Flier, P. Scheltens. Knowing the Natural Course of Biomarkers in AD: Longitudinal MRI, CSF and PET Data. J Nutr Health Aging. 2009; 13(4):353–355
B. Dubois. Interest of the New Criteria for Drug Trials in AD. J Nutr Health Aging. 2009; 13(4):356–357
K. Blennow, H. Zetterberg. Use of CSF Biomarkers in Alzheimer’s Disease Clinical Trials. J Nutr Health Aging. 2009; 13(4):358–361
S.B. Hendrix, G.K. Wilcock. What We Have Learned from the Myriad Trials. J Nutr Health Aging. 2009; 13(4):362–364
P. Douillet, J.-M. Orgogozo. What We Have Learned from the Xaliproden Sanofi-Aventis Trials. J Nutr Health Aging. 2009; 13(4):365–366
C. Wischik, R. Staff. Challenges in the Conduct of Disease-Modifying Trials in AD: Practical Experience from a Phase 2 Trial of Tau-Aggregation Inhibitor Therapy. J Nutr Health Aging. 2009; 13(4):367–369
D. Saumier, P.S. Aisen, S. Gauthier, B. Vellas, S.H. Ferris, A. Duong, J. Suhy, J. Oh, W. Lau, D. Garceau, D. Haine, J. Sampalis. Lessons Learned in the Use of Volumetric MRI in Therapeutic Trials in Alzheimer’s Disease: The ALZHEMEDTM (Tramiprosate) Experience. J Nutr Health Aging. 2009; 13(4):370–372
H. Hampel, K. Broich. Enrichment of MCI and Early Alzheimer’s Disease Treatment Trials Using Neurochemical & Imaging Candidate Biomarkers. J Nutr Health Aging. 2009; 13(4):373–375
C.C. Gispen-de Wied, M. Kritsidima, A.J.A. Elferink. The Validity of Biomarkers as Surrogate Endpoints in Alzheimer’s Disease by Means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES). J Nutr Health Aging. 2009; 13(4):376–387
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vellas, B. Use of biomarkers in Alzheimer’s trials. J Nutr Health Aging 13, 331 (2009). https://doi.org/10.1007/s12603-009-0031-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-009-0031-z